Moleculin Biotech secured Mexican Patent No. 436849 while issuing 888,400 common shares through its ATM offering for $0.48 million. The patent remains in force until November 23, 2040, extending stated protection for its lung-targeted liposomal Annamycin technology and supporting the company’s stated long-term commercial opportunity.
Key Highlights
- Mexican Patent No. 436,849 covers Moleculin Biotech’s lung-targeted liposomal Annamycin technology.
- The company’s ATM offering generated $0.48 million in gross proceeds during September 2026.
- Series I Warrants covering up to 37,130,001 common shares were issued on August 3, 2026.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Pharmaceuticals: Major company. It secured Mexican Patent No. 436,849 for its lung-targeted liposomal Annamycin technology, while its ATM offering produced $0.48 million in aggregate gross proceeds from September share issuances. The patent remains effective until November 23, 2040.
Mexican Patent and ATM Issuance Details
Moleculin said the patent strengthens its international intellectual property protection for the Annamycin formulation designed to target pulmonary tumors and metastatic disease. The company described the grant as supporting longer-term exclusivity for the covered technology and broader development opportunities beyond hematologic malignancies. During September 2026, Moleculin issued 888,400 common shares through the ATM arrangement, with Roth acting as sales agent. After those issuances, 20,385,780 common shares will be outstanding. The update also revised the Economics of the Series I Warrants issued in the public offering on August 3, 2026. Those warrants can be exercised for up to 37,130,001 common shares and initially carried a $0.75 per-share exercise price. Following the ATM share issuance, the exercise price fell to $0.51 per share under the warrants’ anti-dilution provisions, subject to a floor price.
FAQs
Q: What patent did Moleculin Biotech receive in Mexico?
A: Moleculin Biotech received Mexican Patent No. 436,849. The patent covers its lung-targeted liposomal Annamycin technology and remains in force until November 23, 2040.
Q: How much did Moleculin Biotech raise through its ATM offering?
A: Moleculin Biotech issued 888,400 common shares through the ATM offering during September 2026. Those issuances generated aggregate gross proceeds of $0.48 million.
Q: Why was the Series I Warrant exercise price reduced?
A: The Series I Warrant exercise price was reduced under anti-dilution provisions after Moleculin Biotech issued common stock through the ATM offering. It changed from $0.75 to $0.51 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.